Archive · 23 Jun 2025
Novo Nordisk's New Weight-Loss Drug Outperforms Wegovy in Early Trial
A new drug from Novo Nordisk called amycretin is showing promising results for weight loss, even better than their current drug, Wegovy.
Amycretin uses a similar approach to Wegovy, but adds another hormone to help control appetite and blood sugar.
The drug is given as a weekly shot and a daily pill.
Another drug, CagriSema, has similar safety to Wegovy.
The company plans more trials and may offer a stronger dose of Wegovy soon.
The goal is to offer more solutions for people who want to lose weight.
Novo Nordisk's amycretin resulted in over 24% weight loss in early trials.
Amycretin combines the same gut hormone as Wegovy with amylin.
Amycretin was administered as a once-weekly shot and a daily pill.
CagriSema showed a safety profile comparable to Wegovy.
Novo Nordisk plans a late-stage trial for amycretin and a label update for a higher dose of Wegovy.
- Who
- Novo Nordisk developed the drug.
- What
- Early trials show Novo Nordisk's amycretin leads to significant weight loss.
- When
- Data presented at the American Diabetes Association conference.
- Where
- American Diabetes Association conference and published in The Lancet.
- Why
- To develop the next generation of obesity medicines.
- Drug Name
- Amycretin
- Weight Loss (Amycretin)
- Over 24%
- Weight Loss (Wegovy)
- About 17%
- Administration
- Weekly shot and daily pill
- Drug Name 2
- CagriSema
- Company
- Novo Nordisk
- Trial Phase
- Early stage and late-stage planned for amycretin
